On his way out of Alnylam, outgoing CEO John Maraganore, who had led the biotech through thick and thin for 19 years, said late last year he wanted to advise new biotech companies in the grandfather phase of his career.

“It’s like a grandfather, right? You get the benefit of loving your grandchildren, but not having to take care of them all the time,” Maraganore said at the time. “I want to be a granddad.”

Covid-19 has been a rough go for many drugmakers, but few more so than Spectrum Pharmaceuticals, which has seen inspection delays and unwanted CRLs haunt its chance at a first approval. Feeling the sting, Spectrum will now downsize to keep the lights on through the year.

Spectrum will cut 30% of its workforce and pivot its R&D efforts around its two furthest-along drugs as part of a restructuring effort that will pave the company’s cash runway out into next year, it announced Wednesday.

A third former GlaxoSmithKline scientist caught in an alleged plot to steal trade secrets and sell the work in China pleaded guilty to conspiracy on Monday.

Lucy Xi, a 44-year-old scientist, was accused of feeding her former husband, Yan Mei, confidential information on GSK’s research into monoclonal antibodies for his work on a new Chinese biotech company called Renopharma, according to the charges.

The Theranos saga has captivated the pharma world over the last two decades, from its founding to its sharp rise and even sharper decline. And late Monday, its founder and former CEO Elizabeth Holmes was found guilty on several counts related to misleading investors, with each carrying a maximum of up to 20 years in prison.

Jurors returned the verdict Monday evening, finding Holmes guilty on one count of conspiracy to commit wire fraud and three counts of wire fraud against specific investors, with several news outlets reporting on the result. Holmes was found not guilty on four counts related to defrauding patients and jurors deadlocked on three counts of misleading individual investors.

In a stunning climax to an eye-catching saga, Harvard scientist Charles Lieber has been convicted of lying to the federal government about his ties to China’s Thousand Talents Program.

Following close to three hours of deliberation, a federal jury in Boston found 62-year-old Lieber — a pioneer in medical nanotechnology and the former chair of Harvard’s chemistry department — guilty of all six felony charges, including two counts of making false statements, two counts of filing false tax returns and two counts of failing to disclose a foreign (in this case Chinese) bank account.